Will Blopress AG Launched Prior to Patent Expiration Dominate the Market?

The angiotensin receptor blocker (ARB) candesartan (original product: Blopress) will be the first authorized generic (AG) to be launched before the patent of the original product expires. Takeda Pharmaceutical has licensed the patent to ASKA Pharmaceutical. The AG will have...read more